Printer Friendly

Relypsa signs two-year detailing agreement with Sanofi in the US for Patiromer FOS.

M2 PHARMA-August 11, 2015-Relypsa signs two-year detailing agreement with Sanofi in the US for Patiromer FOS

(C)2015 M2 COMMUNICATIONS

Biopharmaceutical company Relypsa (NasdaqGS:RLYP) disclosed on Monday that it has entered into a two-year detailing agreement with Sanofi for Patiromer for Oral Suspension (Patiromer FOS).

According to Relypsa, Patiromer FOS is its investigational medicine that is currently under review for the treatment of hyperkalemia with the US Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date of 21 October 2015.

Patiromer FOS is an oral potassium binder in development for the treatment of hyperkalemia. Hyperkalemia, or abnormally elevated levels of potassium in the blood, can lead to life-threatening cardiac arrhythmia and sudden death. It is frequently prevalent in patients who suffer from CKD, hypertension, diabetes and/or heart failure.

If approved by the US FDA, Relypsa intends to commercialise Patiromer FOS with its own dedicated US based commercial team and specialty sales force of approximately 120 sales representatives. The sales force will focus primarily on outreach to nephrologists, cardiologists and hospitals.

Under the two year agreement, Sanofi's nephrology sales force will complement Relypsa's efforts by detailing Patiromer FOS in the US. Sanofi will be paid a service fee and is also eligible to receive incentive payments. The term may be extended by mutual agreement of both parties.

In conjunction, Relypsa will continue to be responsible for all regulatory, development, commercial, manufacturing and distribution activities for Patiromer FOS in the US, including recording sales.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 11, 2015
Words:261
Previous Article:Impax divests USD55m Daraprim to Turing Pharmaceuticals AG.
Next Article:Cardiome Pharma sets maximum price per vial of BRINAVESS (vernakalant hydrochloride) in the UK.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters